BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 71.46 Million SEK | -78.09% |
| 2022 | 326.12 Million SEK | 1582.45% |
| 2021 | 19.38 Million SEK | -86.85% |
| 2020 | 147.37 Million SEK | 57.21% |
| 2019 | 93.74 Million SEK | 143.18% |
| 2018 | 38.54 Million SEK | -8.51% |
| 2017 | 42.13 Million SEK | -40.06% |
| 2016 | 70.28 Million SEK | 392.39% |
| 2015 | 14.27 Million SEK | -69.58% |
| 2014 | 46.93 Million SEK | -42.56% |
| 2013 | 81.71 Million SEK | 90.27% |
| 2012 | 42.94 Million SEK | -65.55% |
| 2011 | 124.64 Million SEK | 50.42% |
| 2010 | 82.86 Million SEK | 2.74% |
| 2009 | 80.65 Million SEK | -68.01% |
| 2008 | 252.13 Million SEK | 75.78% |
| 2007 | 143.43 Million SEK | 182.2% |
| 2006 | 50.82 Million SEK | 80.26% |
| 2005 | 28.19 Million SEK | -52.0% |
| 2004 | 58.74 Million SEK | -11.94% |
| 2003 | 66.71 Million SEK | -23.36% |
| 2002 | 87.05 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 12.76 Million SEK | 176.82% |
| 2024 Q1 | 5.94 Million SEK | -61.21% |
| 2024 Q2 | 4.61 Million SEK | -22.4% |
| 2023 Q3 | 26.79 Million SEK | 104.64% |
| 2023 Q2 | 13.09 Million SEK | -19.42% |
| 2023 Q1 | 16.25 Million SEK | -21.27% |
| 2023 FY | 71.46 Million SEK | -78.09% |
| 2023 Q4 | 15.31 Million SEK | -42.83% |
| 2022 Q2 | 270.9 Million SEK | 1526.19% |
| 2022 FY | 326.12 Million SEK | 1582.45% |
| 2022 Q4 | 20.64 Million SEK | 15.18% |
| 2022 Q3 | 17.92 Million SEK | -93.39% |
| 2022 Q1 | 16.65 Million SEK | 239.77% |
| 2021 Q4 | 4.9 Million SEK | 63.82% |
| 2021 Q2 | 5.28 Million SEK | -14.71% |
| 2021 FY | 19.38 Million SEK | -86.85% |
| 2021 Q3 | 2.99 Million SEK | -43.4% |
| 2021 Q1 | 6.2 Million SEK | -93.72% |
| 2020 Q1 | 16.71 Million SEK | -34.16% |
| 2020 Q2 | 15.64 Million SEK | -6.38% |
| 2020 Q4 | 98.74 Million SEK | 507.01% |
| 2020 Q3 | 16.26 Million SEK | 3.96% |
| 2020 FY | 147.37 Million SEK | 57.21% |
| 2019 Q1 | 17.4 Million SEK | 67.7% |
| 2019 FY | 93.74 Million SEK | 143.18% |
| 2019 Q3 | 18.05 Million SEK | -45.12% |
| 2019 Q4 | 25.38 Million SEK | 40.62% |
| 2019 Q2 | 32.89 Million SEK | 89.05% |
| 2018 Q1 | 11.33 Million SEK | -16.28% |
| 2018 Q2 | 9.79 Million SEK | -13.58% |
| 2018 FY | 38.54 Million SEK | -8.51% |
| 2018 Q3 | 7.04 Million SEK | -28.05% |
| 2018 Q4 | 10.37 Million SEK | 47.28% |
| 2017 Q4 | 13.53 Million SEK | 89.55% |
| 2017 Q3 | 7.14 Million SEK | -37.16% |
| 2017 Q1 | 12.97 Million SEK | -57.86% |
| 2017 FY | 42.13 Million SEK | -40.06% |
| 2017 Q2 | 11.36 Million SEK | -12.4% |
| 2016 FY | 70.28 Million SEK | 392.39% |
| 2016 Q3 | 812 Thousand SEK | -92.12% |
| 2016 Q2 | 10.3 Million SEK | -64.93% |
| 2016 Q1 | 29.37 Million SEK | 194.26% |
| 2016 Q4 | 30.78 Million SEK | 3691.75% |
| 2015 Q4 | 9.98 Million SEK | 498.56% |
| 2015 FY | 14.27 Million SEK | -69.58% |
| 2015 Q3 | 1.66 Million SEK | -54.4% |
| 2015 Q2 | 3.65 Million SEK | 494.8% |
| 2015 Q1 | 615 Thousand SEK | -63.22% |
| 2014 Q2 | 32.44 Million SEK | 1739.12% |
| 2014 Q4 | 1.67 Million SEK | -84.87% |
| 2014 Q1 | 1.76 Million SEK | -96.47% |
| 2014 FY | 46.93 Million SEK | -42.56% |
| 2014 Q3 | 11.05 Million SEK | -65.93% |
| 2013 Q4 | 49.98 Million SEK | 539.43% |
| 2013 Q2 | 12.27 Million SEK | 5.46% |
| 2013 FY | 81.71 Million SEK | 90.27% |
| 2013 Q1 | 11.63 Million SEK | 25.11% |
| 2013 Q3 | 7.81 Million SEK | -36.31% |
| 2012 Q1 | 14.5 Million SEK | 689.82% |
| 2012 Q3 | 12.88 Million SEK | 106.31% |
| 2012 Q4 | 9.3 Million SEK | -27.82% |
| 2012 FY | 42.94 Million SEK | -65.55% |
| 2012 Q2 | 6.24 Million SEK | -56.94% |
| 2011 Q4 | 1.83 Million SEK | -74.35% |
| 2011 Q3 | 7.16 Million SEK | -60.84% |
| 2011 Q2 | 18.29 Million SEK | -81.21% |
| 2011 Q1 | 97.35 Million SEK | 1404.03% |
| 2011 FY | 124.64 Million SEK | 50.42% |
| 2010 FY | 82.86 Million SEK | 2.74% |
| 2010 Q4 | 6.47 Million SEK | -51.41% |
| 2010 Q3 | 13.32 Million SEK | -72.46% |
| 2010 Q2 | 48.36 Million SEK | 220.28% |
| 2010 Q1 | 15.1 Million SEK | -24.61% |
| 2009 Q3 | 13.5 Million SEK | 24.41% |
| 2009 Q2 | 10.85 Million SEK | -70.54% |
| 2009 FY | 80.65 Million SEK | -68.01% |
| 2009 Q4 | 20.03 Million SEK | 48.3% |
| 2009 Q1 | 36.84 Million SEK | 0.0% |
| 2008 FY | 252.13 Million SEK | 75.78% |
| 2007 FY | 143.43 Million SEK | 182.2% |
| 2006 FY | 50.82 Million SEK | 80.26% |
| 2005 FY | 28.19 Million SEK | -52.0% |
| 2004 FY | 58.74 Million SEK | -11.94% |
| 2003 FY | 66.71 Million SEK | -23.36% |
| 2002 FY | 87.05 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 144.473% |
| Ziccum AB (publ) | -23.28 Million SEK | 406.884% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 79.365% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | -71.013% |
| Mendus AB (publ) | 28.48 Million SEK | -150.855% |
| Genovis AB (publ.) | 54 Million SEK | -32.333% |
| Intervacc AB (publ) | -13.79 Million SEK | 618.059% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -3191.617% |
| Active Biotech AB (publ) | -1.67 Million SEK | 4366.328% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -617.264% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -166.437% |
| Aptahem AB (publ) | 2.63 Million SEK | -2616.479% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 2188.892% |
| Kancera AB (publ) | -1.96 Million SEK | 3736.692% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -92706.494% |
| Fluicell AB (publ) | 1.73 Million SEK | -4011.68% |
| Saniona AB (publ) | 11.78 Million SEK | -506.578% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 1496.541% |
| Biovica International AB (publ) | 6.87 Million SEK | -939.13% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 406.924% |
| AcouSort AB (publ) | 8.38 Million SEK | -751.842% |
| Xintela AB (publ) | 78 Thousand SEK | -91516.667% |
| Abliva AB (publ) | -35.66 Million SEK | 300.379% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 148.646% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -2445.814% |
| OncoZenge AB (publ) | 3000.00 SEK | -2381933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 3802.642% |
| 2cureX AB (publ) | -37.48 Million SEK | 290.629% |
| CombiGene AB (publ) | -21.29 Million SEK | 435.644% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 16993.853% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 93.675% |
| Camurus AB (publ) | 1.58 Billion SEK | 95.479% |
| Corline Biomedical AB | 28.38 Million SEK | -151.801% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 158.224% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 307.645% |
| I-Tech AB | 27.56 Million SEK | -159.236% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | -0.719% |
| Cyxone AB (publ) | 2.61 Million SEK | -2636.921% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -1999.941% |
| Biosergen AB | -456 Thousand SEK | 15771.272% |
| Cantargia AB (publ) | -3.45 Million SEK | 2170.733% |
| NextCell Pharma AB | -43.74 Million SEK | 263.346% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 877.257% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -537.005% |
| Nanologica AB (publ) | -76 Thousand SEK | 94127.632% |
| SynAct Pharma AB | -778 Thousand SEK | 9285.219% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 37126.425% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 653.018% |
| Lipum AB (publ) | 53 Thousand SEK | -134732.075% |
| Alzinova AB (publ) | 19.87 Million SEK | -259.57% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -96.868% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -4784.486% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 476506.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -4210.072% |
| Simris Alg AB (publ) | 2 Million SEK | -3460.588% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 2096.117% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -101.936% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 6912.297% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -2180.913% |